 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ:SYRS, a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter and full year ended December 31, 2020, and provided an update on recent accomplishments and upcoming events. 2021 promises to be a pivotal year for Syros, said Nancy Simonian, M.D., Chief Executive Officer of Syros. We moved our lead program into our first registration-enabling study and continu 